BBP-398 + osimertinib
Phase 1Terminated 0 watching 0 views this week💤 Quiet
25
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedAbout BBP-398 + osimertinib
BBP-398 + osimertinib is a phase 1 stage product being developed by LianBio for NSCLC. The current trial status is terminated. This product is registered under clinical trial identifier NCT06032936. Target conditions include NSCLC.
Hype Score Breakdown
Clinical
10
Activity
5
Company
2
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06032936 | Phase 1 | Terminated |
Competing Products
20 competing products in NSCLC